Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · STOK · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
85
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Stoke Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
STOK insider buying and selling by quarter
STOK insider selling · STOK insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · STOK ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
STOK executive sell shares · STOK board member insider trading · STOK insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 1,795 | $55K | Form 4 |
| May 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 2,243 | $74K | Form 4 |
| Apr 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 1,838 | $60K | Form 4 |
| Mar 20, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 8,692 | $292K | Form 4 |
| Mar 20, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 601 | $21K | Form 4 |
| Mar 17, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 3,577 | $117K | Form 4 |
| Mar 17, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 2,587 | $86K | Form 4 |
| Mar 19, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Option | 1,365 | $3K | Form 4 |
| Mar 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 6,100 | $191K | Form 4 |
| Mar 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 483 | $15K | Form 4 |
| Mar 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 103 | $3K | Form 4 |
| Mar 19, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 1,461 | $44K | Form 4 |
| Mar 17, 2026 | Leggett Thomas CFO | Sale | 1,274 | $42K | Form 4 |
| Mar 17, 2026 | Leggett Thomas CFO | Sale | 922 | $31K | Form 4 |
| Mar 18, 2026 | Leggett Thomas CFO | Sale | 2,173 | $68K | Form 4 |
| Mar 18, 2026 | Leggett Thomas CFO | Sale | 172 | $5K | Form 4 |
| Mar 18, 2026 | Leggett Thomas CFO | Sale | 37 | $1K | Form 4 |
| Mar 17, 2026 | Hoitt Jason Chief Patient Officer | Sale | 1,033 | $34K | Form 4 |
| Mar 17, 2026 | Hoitt Jason Chief Patient Officer | Sale | 748 | $25K | Form 4 |
| Mar 18, 2026 | Hoitt Jason Chief Patient Officer | Sale | 1,762 | $55K | Form 4 |
| Mar 18, 2026 | Hoitt Jason Chief Patient Officer | Sale | 139 | $4K | Form 4 |
| Mar 18, 2026 | Hoitt Jason Chief Patient Officer | Sale | 30 | $986 | Form 4 |
| Mar 17, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 2,476 | $81K | Form 4 |
| Mar 17, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 1,791 | $60K | Form 4 |
| Mar 18, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 4,222 | $132K | Form 4 |
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Date
Mar 20
Shares
8,692
Price
$33.64
Value
$292K
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Date
Mar 20
Shares
601
Price
$34.41
Value
$21K
Ticho Barry
CHIEF MEDICAL OFFICER
Date
Mar 17
Shares
3,577
Price
$32.74
Value
$117K
Ticho Barry
CHIEF MEDICAL OFFICER
Date
Mar 18
Shares
6,100
Price
$31.28
Value
$191K
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Date
Mar 17
Shares
2,476
Price
$32.74
Value
$81K
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Date
Mar 17
Shares
1,791
Price
$33.38
Value
$60K
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Date
Mar 18
Shares
4,222
Price
$31.28
Value
$132K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About STOK insider trading
STOK insider trades
Stoke Therapeutics, Inc. (STOK) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Ticho Barry (CHIEF MEDICAL OFFICER), Allan Jonathan (GENERAL COUNSEL & CORP SEC), Kaye Edward M. MD (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. STOK insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Stoke Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
STOK insider trading · 5 questionsThe insiders of Stoke Therapeutics, Inc. (STOK) include executives and directors such as Ticho Barry (CHIEF MEDICAL OFFICER), Allan Jonathan (GENERAL COUNSEL & CORP SEC), Kaye Edward M. MD (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026